Price Action Don’t Lie: Ultragenyx Pharmaceutical Inc Has Another Very Strong Trading Session

Price Action Don't Lie: Ultragenyx Pharmaceutical Inc Has Another Very Strong Trading Session

The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is a huge mover today! The stock increased 3.44% or $2.36 during the last trading session, hitting $70.94. About 460,836 shares traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 10.08% since February 26, 2016 and is uptrending. It has underperformed by 0.34% the S&P500.
The move comes after 7 months positive chart setup for the $2.68 billion company. It was reported on Oct, 1 by Barchart.com. We have $89.38 PT which if reached, will make NASDAQ:RARE worth $696.80M more.

Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on November, 14. They expect $-1.58 EPS, down 53.40% or $0.55 from last year’s $-1.03 per share. After $-1.46 actual EPS reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 8.22% negative EPS growth.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Ratings Coverage

Out of 12 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 12 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ultragenyx Pharmaceutical Inc has been the topic of 20 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Bank of America given on Tuesday, June 28. H.C. Wainwright initiated the shares of RARE in a report on Tuesday, February 9 with “Buy” rating. The company was initiated on Tuesday, September 1 by Raymond James. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. The firm has “Buy” rating by Zacks given on Tuesday, August 18. The firm has “Neutral” rating given on Tuesday, January 12 by Citigroup. The company was initiated on Thursday, September 3 by Citigroup. The firm has “Buy” rating by Jefferies given on Friday, October 23. Wedbush maintained it with “Outperform” rating and $92 target price in Tuesday, May 10 report. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has “Buy” rating given on Monday, July 13 by SunTrust.

According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.”

Insitutional Activity: The institutional sentiment decreased to 0.97 in 2016 Q2. Its down 0.12, from 1.09 in 2016Q1. The ratio fall, as 19 funds sold all Ultragenyx Pharmaceutical Inc shares owned while 55 reduced positions. 19 funds bought stakes while 53 increased positions. They now own 36.54 million shares or 1.13% less from 36.95 million shares in 2016Q1.
Rock Springs Capital Management L P accumulated 141,500 shares or 0.51% of the stock. Millennium Ltd Liability Corp holds 0.05% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 461,245 shares. Wells Fargo Commerce Mn holds 0.03% or 1.35 million shares in its portfolio. Federated Investors Pa, a Pennsylvania-based fund reported 443,050 shares. Clarivest Asset Mngmt Llc last reported 12,552 shares in the company. Huntington Savings Bank has 0% invested in the company for 311 shares. Cornerstone Capital Management Holdings Ltd Liability Com, a New York-based fund reported 4,431 shares. Axa accumulated 227,213 shares or 0.05% of the stock. Rockefeller Fin Svcs, a New York-based fund reported 396,346 shares. Creative Planning has 4,200 shares for 0% of their US portfolio. Pacad Inv, a British Columbia – Canada-based fund reported 12,200 shares. Macquarie Gru Limited last reported 0% of its portfolio in the stock. Profund Advisors Ltd Co has invested 0.05% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Raymond James And Assoc has invested 0% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Great West Life Assurance Can holds 0% or 2,555 shares in its portfolio.

More news for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) were recently published by: Investorplace.com, which released: “3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx …” on July 14, 2016. Twst.com‘s article titled: “Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Positive Interim Data from …” and published on September 18, 2016 is yet another important article.

RARE Company Profile

Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment